Mar 08, 2022 / 07:50PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good afternoon, and welcome once again to Cowen & Company's 42nd Annual Health Care Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen. It's my pleasure to moderate a fireside chat. We are very happy to have with us today Vertex's President and CEO, Reshma Kewalramani.
Reshma, I'd love to hand it over to you for some opening remarks, and then we'll dive right into the Q&A.
Reshma Kewalramani - Vertex Pharmaceuticals Incorporated - CEO, President & Director
Great. Thanks so much, Phil, and thanks to Cowen for hosting this fireside chat. Hopefully, the last that we'll be doing virtually for years to come, and good afternoon all. Before giving you a top line view of the company, let me just remind the audience that my comments today will include some forward-looking statements, and these are subject to risks and uncertainties discussed in our SEC filings, which I encourage you to review.
Phil, 2021 was a really important
Vertex Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers